PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals

PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals
NovoCure Ltd reports positive trial

NovoCure Ltd announced positive outcomes today from the Phase 2 PANOVA-4 trial evaluating its Tumor Treating Fields (TTFields) therapy.

The company released the results in a press statement, marking a significant milestone for its ongoing research efforts. TTFields therapy is an innovative, non-invasive treatment modality targeting tumor growth. Further details on the trial findings and next steps are available in NovoCure Ltd's official press release.

NovoCure Ltd recently received Japanese government approval for insurance reimbursement of its lung cancer treatment, according to a prior announcement here. The company also delivered its financial results for the quarter and full year ended December 31, 2025 here. These updates provide additional context for NovoCure’s ongoing clinical and commercial initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.